30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Indaptus Therapeutics Inc (INDP)

Track

Stock chart
Ticker: INDP Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Anderson Glen R.
1 purchase — total 56,006 USD
Buy 14 Aug 2023
Value US$4,745,846.78 | Price 372.79 | Shares 70,494
Buy 11 Aug 2023
Value US$4,958,713.31 | Price 86.66 | Shares 47,354
Buy 10 Aug 2023
Value US$86,046.76 | Price 1.94 | Shares 44,354
Buy 1 Dec 2022
Value US$935.45 | Price 1.87 | Shares 500
Buy 22 Nov 2022
Value US$915.00 | Price 1.83 | Shares 500
Buy 21 Nov 2022
Value US$18,240.00 | Price 1.90 | Shares 9,600
Buy 18 Nov 2022
Value US$705.48 | Price 1.76 | Shares 400
Buy 8 Sep 2022
Value US$28,862.40 | Price 2.80 | Shares 10,308
Buy 7 Sep 2022
Value US$393.00 | Price 2.62 | Shares 150
Buy 7 Sep 2022
Value US$22,184.24 | Price 2.57 | Shares 8,632
Buy 6 Sep 2022
Value US$2,586.40 | Price 2.44 | Shares 1,060
Buy 6 Jun 2022
Value US$51,882.01 | Price 2.63 | Shares 19,727
Buy 2 Mar 2022
Value US$204.63 | Price 4.09 | Shares 50
Planned sale 1 Feb 2022
Value US$70,692.39 | Price 5.00 | Shares 14,130
Buy 31 Jan 2022
Value US$465.00 | Price 4.65 | Shares 100
Planned sale 31 Jan 2022
Value US$29,350.59 | Price 5.00 | Shares 5,870
Buy 18 Nov 2021
Value US$65,108.34 | Price 5.82 | Shares 11,187
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-08-16 2023-08-14 B Purchase
2.9
Anderson Glen R.
Large shareholder
70,494 +3.0%
372.79
US$4,745,847 		70,494 +3.0% 372.79 US$4,745,847
2023-08-16 2023-08-11 B Purchase
2.9
Anderson Glen R.
Large shareholder
47,354 +9.4%
86.66
US$4,958,713 		47,354 +9.4% 86.66 US$4,958,713
2023-08-16 2023-08-10 B Purchase
2.9
Anderson Glen R.
Large shareholder
79,080 -22.4%
98.06
US$2,244,104 		79,080 -22.4% 98.06 US$2,244,104
2022-12-19 2022-12-01 B Purchase
1.4
Litchev Boyan Vesselinov

Chief Medical Officer

Officer
500 +76.9%
1.87
US$935 		500 +76.9% 1.87 US$935
2022-12-19 2022-11-22 B Purchase
1.4
Litchev Boyan Vesselinov

Chief Medical Officer

Officer
500 +333.3%
1.83
US$915 		500 +333.3% 1.83 US$915
2022-11-22 2022-11-21 B Purchase
1.9
Meckler Jeffrey A

CEO and Director

Executive Director
9,600 +14.6%
1.90
US$18,240 		9,600 +14.6% 1.90 US$18,240
2022-11-22 2022-11-18 B Purchase
1.9
Meckler Jeffrey A

CEO and Director

Executive Director
400 +0.6%
1.76
US$705 		400 +0.6% 1.76 US$705
2022-09-12 2022-09-08 B Purchase
1.9
Meckler Jeffrey A

CEO and Director

Executive Director
10,308 +18.7%
2.80
US$28,862 		10,308 +18.7% 2.80 US$28,862
2022-09-09 2022-09-07 B Purchase
0.6
Linscott Walt Addison

Chief Business Officer

Officer
150 +inf%
2.62
US$393 		150 +inf% 2.62 US$393
2022-09-08 2022-09-07 B Purchase
1.9
Meckler Jeffrey A

CEO and Director

Executive Director
8,632 +18.6%
2.57
US$22,184 		8,632 +18.6% 2.57 US$22,184
2022-09-08 2022-09-06 B Purchase
1.9
Meckler Jeffrey A

CEO and Director

Executive Director
1,060 +2.3%
2.44
US$2,586 		1,060 +2.3% 2.44 US$2,586
2022-06-07 2022-06-06 B Purchase
1.9
Meckler Jeffrey A

CEO and Director

Executive Director
19,727 +76.9%
2.63
US$51,882 		19,727 +76.9% 2.63 US$51,882
2022-12-19 2022-03-02 B Purchase
1.4
Litchev Boyan Vesselinov

Chief Medical Officer

Officer
50 +50.0%
4.09
US$205 		50 +50.0% 4.09 US$205
2022-02-02 2022-02-01 PlS Planned sale
Newman Michael James

CSO and Director

Executive Director Large shareholder
14,130 -1.0%
5.00
US$70,692 		14,130 -1.0% 5.00 US$70,692
2022-12-19 2022-01-31 B Purchase
1.4
Litchev Boyan Vesselinov

Chief Medical Officer

Officer
100 +inf%
4.65
US$465 		100 +inf% 4.65 US$465
2022-02-02 2022-01-31 PlS Planned sale
Newman Michael James

CSO and Director

Executive Director Large shareholder
5,870 -0.4%
5.00
US$29,351 		5,870 -0.4% 5.00 US$29,351
2021-11-19 2021-11-18 B Purchase
1.9
Meckler Jeffrey A

CEO and Director

Executive Director
11,187 +77.4%
5.82
US$65,108 		11,187 +77.4% 5.82 US$65,108
Explore more

More insider trading research around Indaptus Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America